FRM
NTLA icon

Fox Run Management’s Intellia Therapeutics NTLA Stock Holding History

Fox Run Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,792
Closed -$298K – 1140
2025
Q2 		$298K Buy
31,792
+13,289
+72% +$109K 0.05% 639
2025
Q1 		$132K Buy
+18,503
New +$187K 0.02% 847
2024
Q1 		– Sell
-19,038
Closed -$580K – 980
2023
Q4 		$580K Buy
19,038
+8,282
+77% +$238K 0.15% 244
2023
Q3 		$340K Buy
+10,756
New +$417K 0.1% 394
2023
Q2 		– Sell
-11,119
Closed -$414K – 875
2023
Q1 		$414K Buy
+11,119
New +$436K 0.14% 283
2022
Q2 		– Sell
-4,578
Closed -$333K – 679
2022
Q1 		$333K Buy
+4,578
New +$388K 0.19% 236
2018
Q1 		– Sell
-11,970
Closed -$230K – 861
2017
Q4 		$230K Buy
+11,970
New +$276K 0.07% 537

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fox Run Management's NTLA Position: Q3 2025 in Review

Fox Run Management sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 31,792 shares — an estimated $298K sold.

Fox Run Management first reported a position in NTLA in Q4 2017 and held it in 7 quarters. The position peaked at $580K in Q4 2023. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • Fox Run Management reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Fox Run Management sold 31,792 Intellia Therapeutics shares in Q3 2025, an estimated $298K.
  • Fox Run Management first reported a position in Intellia Therapeutics in Q4 2017 and held it in 7 quarters.
  • Fox Run Management's Intellia Therapeutics position peaked at $580K in Q4 2023.
  • 282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Fox Run Management's 13F filing for Q3 2025, filed 12 Nov 2025.